Trending News

#Collaboration #Research study

This week in drug discovery (10-14 January) 

News round-up by DDW’s Megan Thomas for 10-14 January, 2022  Studies, approvals and research are at the heart of drug discovery, which has been exemplified in this week’s drug discovery news. Megan Thomas has rounded up her top five stories of the week.   Vaccine-like mRNA injection can be… Read More

#News #Trending News

#Awards #Events #SLAS #SLAS2022

Who are the SLAS2022 Innovation Award finalists? 

With SLAS2022 confirmed to go ahead as both an in-person and hybrid event, the Innovation Award finalist presentations will take place on February 8, from 10AM- 5PM, and will be live-streamed to the online audience.   What is the SLAS Innovation Award? The SLAS Innovation Award consists… Read More

#News #Trending News

#Lab automation #Laboratory data

DDW Winter issue features exclusive SLAS2022 supplement  

The Winter issue of the Drug Discovery World Magazine is out now.   Featuring Specialty Spotlight on Ophthalmology, the magazine is available to download and read for free on the DDW App.   Key features of the Winter Issue include: How Quantum Computing Can Benefit Drug Discovery, Why The Emergence of Targeted Protein Degradation is So Exciting, plus exclusive interviews and… Read More

#News #Trending News

#Whitepaper

Whitepaper: Process optimisation in antibody discovery workflows

Discover how process optimisation utilising automated synthetic biology solutions can remove the antibody sequence cloning bottleneck that divides high-content lead identification and downstream high throughput characterisation. If your work involves antibody discovery or process improvement in recombinant cloning don’t miss this whitepaper illustrating how Codex DNA’s synthetic biology solutions can… Read More

#News #Trending News

#Antibodies #Biotherapeutics #Covid variants #Covid-19 #Omicron

Antibody neutralises Omicron and Delta in live virus studies 

Revelar Biotherapeutics and Twist Bioscience have announced that RBT-0813 binds to and neutralises the Omicron and Delta variants of SARS-CoV-2 in live virus studies.   What is RBT-0813?  RBT-0813 is a bispecific antibody discovered by Twist Biopharma and licensed to Revelar Biotherapeutics that targets epitopes on the SARS-CoV-2 spike protein. Revelar has continued… Read More

#News #Trending News

#Covid variants #Covid-19 #Immunology / Virology & Vaccines

New data on antiviral efficacy against SARS-CoV-2 variants  

Marinomed Biotech, an Austrian biotech company, has announced results of the antiviral efficacy of iota-carrageenan (Carragelose) against the original SARS-CoV-2 strain and variants of concern (VOC), including the Delta variant. This has been published in the International Journal of Molecular Sciences.   Collaboration   The peer-reviewed study is… Read More

#Covid-19 #News #Trending News

#CAR-T #GlobalData #Immunotherapy

Analysts expect competition in CAR-T therapies in Japan 

Janssen Pharmaceutical has recently filed for B-cell maturation antigen (BCMA) CAR-T therapy Cilta-cel in Japan. Earlier in March 2021, Bristol-Myers Squibb (BMS) filed for the first BCMA CAR-T therapy idecabtagene vicleucel, in the country. Following approval by the Japanese regulatory authority, BMS will have the first-mover advantage. However, stiff competition is expected… Read More

#News #Trending News

#Clinical trials #Data #FDA #HIV

HIV prevention options expanded in the US 

The US Food and Drug Administration (FDA) has approved a long-acting HIV prevention medication for the first time.   The drug  Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months. The FDA has approved the medicine for use by adults and adolescents weighing… Read More

#News #Trending News

#Covid-19 #Healthcare #Immunology / Virology & Vaccines #Public health

European Commission authorises Novavax Covid-19 vaccine

Novavax has been granted conditional marketing authorisation by the European Commission (EC) for Nuvaxovid Covid-19 vaccine.  Context  The vaccine is for active immunisation to prevent Covid-19 caused by SARS-CoV-2 in individuals 18 years of age and older and the authorisation follows the European Medicines Agency’s (EMA) Committee for Medicinal… Read More

#Covid-19 #News #Trending News

#Covid-19 #Research study #T-Cells

How is Japan keeping Covid-19 cases so low? 

Research by the Riken Institute in Tokyo, published in the British journal Communications Biology, offers an explanation for Japan’s success in tackling the Covid-19 pandemic when compared with other countries. The research is a piece of the puzzle of why there remains relatively low rates of death and serious… Read More

#Covid-19 #News #Trending News

This week in drug discovery (13-17 December) 

News round-up by DDW’s Megan Thomas for 13-17 December   One of the key pillars of drug discovery and development is research, from studies to trials. This week, DDW’s Megan Thomas has selected five stories which spotlight this important, early work.   1. 4D Pharma presents… Read More

#News #Trending News

#Covid-19 #Healthcare #Immunology / Virology & Vaccines #Public health #Research

NIH scientists urge pursuit of universal coronavirus vaccine 

Physician-scientists of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have published a paper in The New England Journal of Medicine which suggests that in order to counter future coronavirus outbreaks, the global scientific and medical research community should focus… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #AstraZeneca #Drug targets #Immunology

AstraZeneca uses AI platform to target idiopathic pulmonary fibrosis 

AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF) to its drug development portfolio, discovered using BenevolentAI’s platform. This is reportedly the second novel target from the collaboration that has been identified, validated, and selected for AstraZeneca’s portfolio.   The collaboration  BenevolentAI’s collaboration with AstraZeneca currently focuses… Read More

#News #Trending News

#Antivirals #Covid-19 #FDA #Immunology / Virology & Vaccines #Pfizer

Pfizer Covid pill effective against severe disease 

Pfizer has announced results from an analysis of 2,246 adults enrolled in its Phase II/III EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial of its novel Covid-19 oral antiviral candidate Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets).   The results   These results show that  Paxlovid significantly reduced the… Read More

#Covid-19 #News #Trending News